Myriad Genetics (MYGN) Net Cash Flow (2009 - 2026)

Myriad Genetics (MYGN) has reported Net Cash Flow for 18 consecutive years, with -$25.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.09% year-over-year to -$25.2 million; the TTM figure through Mar 2026 stood at $24.4 million (up 642.22% YoY), while the FY2025 annual figure was $38.6 million, up 237.86% from the prior year.
• Net Cash Flow eased to -$25.2 million in Q1 2026 per MYGN's latest filing, from -$3.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $71.1 million in Q3 2025 and bottomed at -$92.6 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$7.8 million across 5 years, with a median of -$3.6 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 1294.12% in 2025 and fell as far as 1178.57% in 2025.
• Myriad Genetics' Net Cash Flow stood at -$45.0 million in 2022, then surged by 222.67% to $55.2 million in 2023, then slumped by 94.93% to $2.8 million in 2024, then slumped by 228.57% to -$3.6 million in 2025, then plunged by 600.0% to -$25.2 million in 2026.
• Business Quant data shows MYGN's Net Cash Flow at -$25.2 million in Q1 2026, -$3.6 million in Q4 2025, and $71.1 million in Q3 2025.